ELFONIS 400mg/250ml price in UAE

Overview

Welcome to Dwaey, specifically on ELFONIS 400mg/250ml Infusion/Solution for page.
This medicine contains an important and useful components, as it consists of Moxifloxacin hydrochloride.
ELFONIS 400mg/250ml is available in the market in concentration 400mg/250ml and in the form of Infusion/Solution for.

HEMOFARM AD VRSAC is the producer of ELFONIS 400mg/250ml and it is imported from REPUBLIC OF SERBIA, The most popular alternatives of ELFONIS 400mg/250ml are listed downward .

Mode Of Action

Moxifloxacin inhibits the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair and recombination.

Indication

Intra-abdominal infections
Chronic bronchitis
Acute bacterial sinusitis
Community-acquired pneumonia
Skin and skin structure infections
Typhoid Fever

Precaution

Maintain adequate fluid intake; Patient w/ previous tendon disorders (e.g. rheumatoid arthritis), significant bradycardia or acute myocardial ischaemia, heart failure w/ reduced LVEF, known history of symptomatic arrhythmias, known or suspected CNS disorders (e.g. severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures; diabetes. Kidney, heart or lung transplant recipients. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and lightheadedness, if affected do not drive or operate machinery. Rest and refrain from doing strenuous physical activity as it may increase risk of tendon rupture. Avoid exposure to sunlight or artificial UV light (e.g. tanning beds, UVA/UVB treatment) and use protective measures (e.g. sunscreen, wear loose-fitting clothes) if staying outdoors is necessary during therapy. Monitoring Parameters Monitor WBC and signs of infection.

Side Effects

1-10% Nausea (7%)
Diarrhea (6%)
Dizziness (3%)
Decreased amylase (2%)
Decreased basophils
eosinophils
hemoglobin
prothrombin time
red blood cells
neutrophils (2%)
Decreased serum glucose (2%)
Increased serum chloride (2%)
Increased serum ionized calcium (2%)
Immune hypersensitivity reaction (0.1-2%)
Prolonged QT interval (0.1-2%) <1% Acute renal failure
Agranulocytosis
Anaphylactoid reaction
Aplastic anemia
Extrinsic allergic alveolitis
Hemolytic anemia
Hepatic failure
Hepatic necrosis
Hepatitis
Pancytopenia
Seizure
Serum sickness due to drug
Stevens-Johnson syndrome
Tendon rupture
tendinitis
Thrombocytopenia
Torsades de pointes
Toxic epidermal necrolysis

Contra indication

Known hypersensitivity to moxifloxacin, other quinolones. Patients w/ known prolongation of QT interval, uncorrected hypokalaemia, myasthenia gravis. Concurrent use of class Ia (e.g.quinidine, procainamide, class III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents).

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine. Potentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.